Business Context and Reporting Period
This Form 8-K filing by Seastar Medical Holding Corp (NASDAQ: ICU) reports a corporate governance event dated January 10, 2024. The company is an emerging growth company incorporated in Delaware, focused on medical device development.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
- Appointment of CFO: David Green was appointed Chief Financial Officer, effective January 10, 2024.
- Role Transition: Caryl Baron transitioned from Interim CFO (a role held since October 2022) to Vice President of Finance.
Management Commentary, Risks, and Unusual Items
Compensatory Arrangements for David Green
- Base Salary: $375,000 annually.
- Annual Bonus: Eligible for up to 40% of base salary based on personal and company performance.
- Equity Grant: 450,000 restricted stock units (RSUs). Vesting schedule: 25% on the first anniversary; remaining 75% monthly over 36 months.
- Financing Bonus: Potential cash and equity bonus if the company completes financing transactions with gross proceeds of $15,000,000 or more.
- Severance: In the event of termination without cause or resignation for good reason (including within 12 months of a change of control), Mr. Green is eligible for 12 months of continued base salary, COBRA coverage, and accelerated vesting of outstanding stock options.
Background
Mr. Green brings experience as CFO for BlackSwan Vascular, LamaMed Solutions, and Aytu BioSciences, and previously served as Interim CFO for Prolacta Biosciences. He is a Certified Public Accountant with an MBA from the University of Rochester.
Investor Verification Checklist
- Verify the full text of the Employment Agreement (Exhibit 10.1) for specific performance metrics tied to the annual bonus.
- Confirm the current status of the company's cash reserves and runway given the new fixed salary obligation of $375,000 plus potential bonuses.
- Review the press release (Exhibit 99.1) for additional strategic context regarding the leadership change.
- Monitor future filings for any financing transactions exceeding $15 million that would trigger the additional bonus clause.